期刊文献+

恶性肿瘤患者医院感染的特点及危险因素分析 被引量:17

Characteristics and Risk Factors of Nosocomial Infectionsin Patients with Malignant Tumor
下载PDF
导出
摘要 目的探讨恶性肿瘤患者发生医院感染的特点及危险因素。方法采用卡方检验分析恶性肿瘤患者医院感染的临床特点;单因素及多因素Logistic回归分析恶性肿瘤患者医院感染的危险因素。结果恶性肿瘤患者医院感染部位以肺部感染为主(48.48%);病原菌依次为革兰阴性菌(70.8%)、革兰阳性菌(21.3%)及真菌(7.9%)。单因素和多因素Logistic回归分析显示,性别、年龄、住院时间、肿瘤分期、侵入性操作是独立危险因素(均为P<0.05)。结论恶性肿瘤患者以男性、≥65岁、住院时间>30 d、肿瘤分期Ⅳ期以下、有侵入性操作等为发生医院感染的高危因素。 Objective To investigate the characteristics and risk factors of nosocomial infection in patients with malignant tumors.Methods Chi-square test was used to analyze the clinical characteristics of nosocomial infection in patients with malignant tumors.Univariate and multivariate logistic regression were used to analyze the risk factors of nosocomial infection in patients with malignant tumors.Results Pulmonary infection(48.48%)was the main infection site in patients with malignant tumor.The pathogenic bacteria were gram negative(70.8%),gram positive(21.3%)and fungal(7.9%),respectively.Univariate and multivariate logistic regression analysis showed that gender,age,length of hospital stay,cancer's clinical stage,and invasive surgery were independent risk factors(P<0.05).Conclusion Male,age of 65 or older,30 days or longer in hospital,cancer clinical stageⅠthroughⅢ,and invasive procedures are risk factors for nosocomial infection in patients with malignant tumors.
作者 吴明铭 杨海涛 林万尊 谢贤和 WU Mingming;YANG Haitao;LIN Wanzun;XIE Xianhe(Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China)
出处 《福建医科大学学报》 2020年第1期48-52,共5页 Journal of Fujian Medical University
关键词 肿瘤 交叉感染 药物耐受性 危险因素 neoplasms cross infection drug tolerance risk factors
  • 相关文献

参考文献11

二级参考文献92

  • 1邹惠娟,孙波.医院感染管理探讨[J].中国疗养医学,2011,20(6):571-573. 被引量:8
  • 2马菲,李东力.医院感染流行病学研究现状[J].解放军预防医学杂志,2006,24(5):386-389. 被引量:14
  • 3中华人民共和国卫生部.医院感染诊断标准[S].北京:中华人民共和国卫生部,2001.1-35.
  • 4Clinical and laboratory Standards Institute. Performance Stand-ards for Antimicrobial Susceptibility testing [ S]. M100-S20.CLSI,2010.
  • 5Clinical and laboratory Standards Institute. Performance Standards for Antimierobial Susceptibility testing [S]. M100-S20. CLSI, 2010.
  • 6Xue L,Yao K,Xie G,et al.Serotype distribution and antimicrobial resistance of Streptococcus pneumonia isolates that cause invasive disease among Chinese children[J].Clin Infect Dis,2010,50(5):741-744.
  • 7Bang YJ,Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oe- sophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial [J]. The Lancet, 2010, 376 (9742) : 687-697.
  • 8RoselI R,Carcereny E,Gervais R,etal. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multieentre, open-label, randornised phase 3 trial [J]. The lancet oneology,2012,13(3) : 239-246.
  • 9Zhou C,Wu Y L,Chen G,et al. Erlotinib versus chemothera- py as first-line treatment for patients with advanced< i> EGFR</i > mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multieentre, open-label, randomised, phase 3 study[J]. The lancet oneology, 2011,12 (8) :735-742.
  • 10Gould IM. Antibiotic policies to control hospital-acquired in- fection[J] J Antimicrob Chemother, 2008,61(4) : 763-765.

共引文献150

同被引文献218

引证文献17

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部